STATEMENT OF NEED
Breast cancer is the most diagnosed cancer in women, with hormone receptor (HR)–positive/human epidermal growth factor receptor 2 (HER2)–negative breast cancer being the most common subtype, making up 73% of cases (ACS, 2019). In breast cancer, phosphatidylinositol-3-kinase (PI3K) overactivation is often associated with an activating mutation in the catalytic alpha subunit of PI3K (PIK3CA). These activating mutations occur in more than one third of breast cancers (Verret et al, 2019). The PI3K/Akt signaling pathway is strongly associated with cell proliferation, migration, and survival and is commonly activated in cancer. Alpelisib was the first PI3K inhibitor approved for breast cancer in 2019, in combination with fulvestrant for patients with metastatic HR-positive/HER2-negative breast cancer and a PIK3CA activation mutation (Andre et al, 2019). In this session, Janie Metsker, RN, BSN, CN-BN will explore the role of PI3K inhibitors for patients with breast cancer, including the advantages of isoform-specific inhibition of PI3K with alpelisib. She will explain how PI3K inhibition is thought to help overcome resistance to hormonal therapy for breast cancer and will review the safety concerns associated with PI3K agents.
Oncology nurses, nurse practitioners, physician assistants, pharmacists, oncologists, and other health care professionals involved in the treatment of patients with breast cancer.
- Assess the indications and safety and efficacy profiles of novel PI3K inhibitors for breast cancer
- Evaluate clinical tools for assessing and grading adverse events associated with novel PI3K inhibitors
- Apply strategies to optimize the safety and tolerability of novel PI3K inhibitors
- Develop educational strategies to help patients understand the benefits and risks of their breast cancer treatment plan
Janie Metsker, RN, BSN, CN-BN
Saint Luke's Hospital
Koontz Center for Advanced Breast Cancer
There is no fee to participate in or claim CME/NCPD/CPE credit for this activity.
i3 Health is accredited by the American Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
i3 Health designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.0 hours of Category 1 credit for completing this program.
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Continuing Pharmacy Education
St. John Fisher University Wegmans School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. UAN # 0584-9999-22-051-H05-P is eligible for 1.0 ACPE CE hours
Nursing Continuing Professional Development
i3 Health is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
A maximum of 1.0 contact hours may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 0.9 hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 contact hours.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.
OCN®, CPHON®, CBCN®, AOCNP®, AOCNS®, and BMTCN® renewal candidates may apply 0.75 ILNA points toward:
- Coordination of Care (CBCN®)
- Diagnosis and Staging (CBCN®)
- Nursing Practice (CBCN®)
- Oncology Nursing Practice (OCN®)
- Symptom Management, Palliative Care, Supportive Care (OCN®, CPHON®, AOCNP®)
- Treatment (OCN®, CBCN®, AOCNP®)
Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of NCPD awarded from this course.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES
i3 Health and St. John Fisher University Wegmans School of Pharmacy (WSOP) endorse the standards of the ACCME, ACPE, and ANCC that require everyone in a position to control the content of a CME/NCPD/CPE activity to disclose all financial relationships with commercial interests that are related to the content of the CME/NCPD/CPE activity. CME/NCPD/CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CME/NCPD/CPE content about products or services of a commercial interest with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health and St. John Fisher University Wegmans School of Pharmacy (WSOP) will identify, review, and mitigate all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health and St. John Fisher University Wegmans School of Pharmacy (WSOP) do not endorse any products or services.
Relevant financial relationships exist between the following individuals and commercial interests:
The i3 Health planners, reviewers, and managers have nothing to disclose.
St. John Fisher University Wegmans School of Pharmacy (WSOP) staff members have no relevant financial relationships to disclose.
Janie Metsker, RN, BSN, CN-BN, discloses that she has served on an advisory board or panel for AstraZeneca and Pfizer.
i3 Health has mitigated all relevant financial relationships.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.
Technology Requirements For Virtual CME | NCPD | CPE Activities
For virtual (asynchronous, archived live, home study; synchronous webinars) CME/NCPD/CPE activities, include access to system requirements:
- The Internet browser(s) supported and minimum versions of each required by the learner to complete the online activity.
- The minimum memory, storage, processor, and Internet speeds require by the learner to complete the online activity.
UNAPPROVED USE DISCLOSURE
i3 Health and St. John Fisher University Wegmans School of Pharmacy (WSOP) require CME/NCPD/CPE faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.
This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
The information provided at this CME/NCPD/CPE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a health care provider relative to diagnostic and treatment options of a specific patient’s medical condition.
This activity is supported by independent educational grants from Gilead Sciences, Inc. and Puma Biotechnology.
Aggregate participant data will be shared with commercial supporters of this activity.